Cannabis Law Report

DECEMBER 3, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We Relative changes in alpha/delta ratio and suppression ratio correlated with measured serum ganaxolone levels.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. Pennsylvania-based Groff North America is one of the companies that is getting a green light to experiment with the plant. territories.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

MMJ Recs

APRIL 1, 2024

We’re exploring the world of CBD, uncovering the benefits of CBD in medical marijuana, its impact on health, its potential as a treatment option, and what you need to know about its use in medical marijuana. CBD: A Promising Treatment Option One of the most compelling aspects of CBD is its versatility as a treatment option.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

DECEMBER 11, 2021

A Manchester MP’s bid to open up cannabis treatments on the NHS has been blocked by Tory backbenchers in the House of Commons. 'A Despite the Government legalising medicinal cannabis in 2018, following a number of high-profile campaigns, thousands of people are still being denied access to the treatment. Read more at.

Treatment 52

Treatment Access Patients Medicine 52

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. In 2020, the law changed to allow patients with any medical condition to receive a doctor’s recommendation to use and purchase medical marijuana products containing a maximum 10 milligrams of THC.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 29, 2022

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd.

Epilepsy 52

Epilepsy Conditions Media Medicine 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

JULY 30, 2019

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. The US approval of Zogenix’s Fintepla, a potential competitor for GW’s drug, has been delayed but still lo… The European Pharmaceutical Review reports.

Epilepsy 40

Epilepsy Pharmaceutical Medicine Treatment 40

Cannabis Law Report

SEPTEMBER 28, 2021

In this case, the patient needs to look for the best ways to treat pain and improve their life quality. Acupuncture is one of the safest alternative forms of treatment for chronic pain. Ideally, it should be used in combination with other therapies, such as herbal medicine and massage, and can be a great addition to other treatments.

Treatment 52

Treatment Chronic Pain Therapy Tincture 52

MGC Pharma

NOVEMBER 1, 2017

This is a big moment for me and the MGC Pharmaceuticals team. Needless to say, I have been waiting a long time to write the following sentence: MGC Pharmaceuticals has just released their first product to the market. CannEpil™ is CBD-based medication that is used as a treatment for people with refractory epilepsy.

Epilepsy 100

Epilepsy Pharmaceutical Medicine CBD 100

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D.,

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

JANUARY 15, 2019

British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”.

Epilepsy 71

Epilepsy Cannabinoids Treatment Research and Development 71

Otherside Farms

JANUARY 24, 2019

Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. Although both studies will enroll 25 patients initially, the U.S. Source: FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials. In the upcoming U.S.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

CannaTech

JANUARY 16, 2019

Thanks to the recent emergence of regulated medical cannabis markets, the success of this versatile plant can be followed from farm to pharma and prescriber to patient, however, the origins of cannabis as medicine cannot be as simply traced as the plant is today from seed to sale. Of course, patients need product and product costs money.

Access 89

Access Patients Pharmaceutical Education 89

United Patients Group

APRIL 18, 2023

Because they often combine it with other drugs like cocaine or heroin or even legal ‘prescribed’ pharmaceuticals–and those are far more dangerous than cannabis itself! In fact, there are some patients who prefer not to smoke because of their health conditions or other reasons. Myth: Cannabis is a cure-all.

Research and Development 108

Research and Development Indica Treatment Conditions 108

WeedAdvisor

JANUARY 8, 2019

For decades, marijuana for cancer treatment seemed out of the question. Even if trials were successful, it is safe to say that using marijuana to treat cancer would meet resistance from the pharmaceutical companies and medical communities alike. The Endocannabinoid System in Cannabis Cancer Treatment.

Treatment 75

Treatment Research and Development Cannabinoids THC 75

MGC Pharma

APRIL 4, 2018

A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals. CBD-based treatment for people with Refractory Epilepsy?—?is Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CannEpil™?—?CBD-based

Epilepsy 100

Epilepsy Pharmaceutical Research and Development CBD 100

MMJ Recs

FEBRUARY 18, 2024

Patients often report improvements in the specific symptoms they sought to alleviate and their overall sense of well-being. Neuroprotective Benefits: Research suggests that CBD may have neuroprotective properties, offering potential benefits for conditions involving neurodegeneration, such as multiple sclerosis and certain forms of epilepsy.

Chronic Pain 52

Chronic Pain Marijuana Epilepsy Research and Development 52

Cannabis Law Report

AUGUST 4, 2022

Following the keenly anticipated June approval of its cannabis-derived Epidiolex, GW Pharmaceuticals $GWPH has finally launched the rare epilepsy drug in the United States. Most patients that suffer from these disorders require a host of seizure medications, and a majority are resistant to existing anti-epileptic therapies.

Epilepsy 52

Epilepsy Therapy Patients Treatment 52

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. The FDA Adds a New Condition for Treatment. However, there is one notable example—Epidiolex. What is Epidiolex?

Access 98

Access Epilepsy Treatment Conditions 98

Veriheal

SEPTEMBER 27, 2021

The society launched a campaign with the hashtag #ApprovedButDenied protesting the difficulty so many patients have faced attempting to obtain medical cannabis. Medical cannabis has been legal in the nation for almost three years—so why are MS patients struggling to access the treatment? ApprovedButDenied.

Treatment 98

Treatment Patients Access Research and Development 98

Cannabis Law Report

JULY 7, 2022

filed a petition requesting inter partes review of claims 1-13 of GW Pharmaceutical Ltd.’s s patent directed to the use of cannabinoids, including cannabidiol (“CBD”), in the treatment of certain types of epilepsy. GW Pharma Limited and Otsuka Pharmaceutical Co., Insys Development Company, Inc. IPR2017-00503, Paper No.

Epilepsy 52

Epilepsy Pharmaceutical Treatment Cannabinoids 52

MMJ Recs

FEBRUARY 3, 2024

In recent years, the landscape of medical marijuana laws has evolved, presenting new opportunities and challenges for patients, healthcare providers, and industry stakeholders. Understanding these regulations is crucial for patients, caregivers, and dispensaries alike to ensure compliance with the law.

Legislation 52

Legislation Law Marijuana Dispensary 52

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

TheAnswerPage

JUNE 29, 2022

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. Has CBDV been evaluated as an anti-seizure medication in clinical trials? That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

JULY 24, 2019

But it is important that access to it is delivered in a way that fits in with other treatment options. Our clinics are based on the premise that patients are treated by our world-renowned specialists in the relevant condition.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. An estimated 250 patients a month are said to be prescribed cannabis medicines through the NHS compared to over 2,500 in the UK’s private sector. Step In Right Direction.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. “Our Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

MGC Pharma

DECEMBER 12, 2017

A word from Elad Segev, Manager of Breeding and Cultivation at MGC Pharmaceuticals. Firstly, recent research has suggested that THC can help relieve pain in many patients. This effect can be put to very good use to help patients suffering from cancer or HIV/AIDS eliminate any uncomfortable nausea that their treatments provoke.

Epilepsy 100

Epilepsy Cannabinoids Pharmaceutical THC 100

TheAnswerPage

JANUARY 9, 2022

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. Has CBDV been evaluated as an anti-seizure medication in clinical trials? That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

SpeedWeed

AUGUST 9, 2021

The first supply of medical cannabis for pediatric patients with epilepsy at the Buenos Aires National Children’s Garrahan Hospital was finally delivered. The hospital’s young patients will now receive treatment from pharmaceutical-grade cannabis oil, purified and highly concentrated. Shutterstock.

Epilepsy 52

Epilepsy Research and Development Medicine Patients 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52